SCHEMBL22807296

SCHEMBL22807296

COC(OC)c1cc(C)c2cccnc2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.42
CCR8 P51685 1/20 0.42
IDO1 P14902 2/20 0.37
HCAR2 Q8TDS4 3/20 0.34
IGF1R P08069 1/20 0.34
NPC1 O15118 1/20 0.34
HSP90AA1 P07900 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CYP1A2 P05177 1/20 0.34
KMT2A Q03164 1/20 0.34
RAB9A P51151 1/20 0.34
ACHE P22303 1/20 0.34
ABCG2 Q9UNQ0 2/20 0.33
CYP2C9 P11712 1/20 0.33
NOS1 P29475 1/20 0.33
NOS2 P35228 1/20 0.33
BACE1 P56817 1/20 0.33
DHODH Q02127 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22828303 0.89 CCR1 (0.37) CCR1CCR8IDO1HCAR2IGF1R
SCHEMBL31613257 0.76 CCR1 (0.41) CCR1CCR8IDO1HCAR2NPC1
SCHEMBL10715826 0.76 CYP1A2 (0.51) CCR1CCR8IDO1HCAR2IGF1R
SCHEMBL14227400 0.74 CYP1A2 (0.52) CCR1CCR8IDO1IGF1RNPC1
SCHEMBL325226 0.73 LMNA (0.46) CCR1CCR8HSP90AA1L3MBTL1KMT2A
SCHEMBL1577423 0.71 CCR1 (0.49) CCR1CCR8IDO1IGF1RNPC1
SCHEMBL19017897 0.71 CCR1 (0.49) CCR1CCR8IDO1HCAR2NPC1
SCHEMBL25082354 0.70 CCR1 (0.47) CCR1CCR8IDO1HCAR2NPC1
SCHEMBL26740996 0.69 CCR1 (0.42) CCR1CCR8IDO1CYP1A2ACHE
SCHEMBL15976490 0.68 KDM4E (0.49) CCR1CCR8NPC1HSP90AA1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220362245-A1 COMPOUNDS FOR INHIBITING FGFR4 TERNS PHARMACEUTICALS, INC. (US) 2022-11-17 US disclosed
EP-3986405-A1 COMPOUNDS FOR INHIBITING FGFR4 Terns Pharmaceuticals, Inc. (US) 2022-04-27 EP disclosed
CN-114144176-A Compounds for inhibiting FGFR4 拓臻制药公司 2022-03-04 CN disclosed
WO-2020257527-A1 COMPOUNDS FOR INHIBITING FGFR4 Terns, Inc. (US) 2020-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220362245-A1 COMPOUNDS FOR INHIBITING FGFR4 FGFR4, FGFR1, FGFR3 CCR1 4713/4885CCR8 4329/4885IDO1 4834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.